Animal Care Receives its First Commercial Order for a TSE System from a Large Animal Clinic in Sweden

Scandinavian ChemoTech’s subsidiary Vetiqure AB, proudly announces an order, for a complete TSE system including consumables, worth approximately EUR 40,000 from a prominent a leading clinic in oncological animal care in Sweden, which is a part of one of the largest veterinary medicine organisations.

This significant order is a result of an extensive evaluation period where the hospital evaluated vetIQure™ and the TSE treatment.

"We are happy to be able to continue to build on our relationship and hope that this collaboration will expand to other hospitals and clinics in Europe and the USA," says Mohan Frick, CEO of Scandinavian ChemoTech and Vetiqure. "This order is a testament to hard work and validates the innovative solutions we have developed to meet the needs of the veterinary and animal care industry. We look forward to a continued successful partnership that will drive growth and create new opportunities for both companies."

As Vetiqure AB continues its journey and begins a new chapter, our focus will continue to be on providing world-class innovation. This marks a continued investment in improving methods and contributes to the establishment of new standards in veterinary medicine's cancer and tumour care.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-09-2024 09:13 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.